| Entry |
|
|---|
| Name |
Dasatinib (USAN);
Dasatinib hydrate (JAN);
Sprycel (TN) |
|---|
| Product |
|
|---|
| Generic |
DASATINIB (Alembic Pharmaceuticals Limited), DASATINIB (Apotex Corp.), DASATINIB (Aurobindo Pharma Limited), DASATINIB (AvKARE), DASATINIB (Biocon Pharma), DASATINIB (BluePoint Laboratories), DASATINIB (Dr.Reddys Laboratories), DASATINIB (Prasco Laboratories), DASATINIB (Teva Pharmaceuticals), DASATINIB (Zydus Lifesciences Limited), DASATINIB (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C22H26ClN7O2S. H2O
|
|---|
| Exact mass |
505.1663
|
|---|
| Mol weight |
506.02
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00714): | D03658<JP> D06414<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
|---|
| Disease |
Chronic myeloid leukemia (Philadelphia chromosome positive) [DS: H00004] Acute lymphoblastic leukemia (Philadelphia chromosome positive) [DS: H00001] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Network |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA02 Dasatinib
D06414 Dasatinib (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, BCR-ABL
Dasatinib
D06414 Dasatinib (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D06414 Dasatinib (USAN); Dasatinib hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00714 Dasatinib
D06414 Dasatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00714 Dasatinib
D06414 Dasatinib
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00714 Dasatinib
D06414 Dasatinib
DG02924 UGT substrate
DG00714 Dasatinib
D06414 Dasatinib
Drug classes [BR:br08332]
Antineoplastic
DG03161 BCR-ABL inhibitor
D06414 Dasatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRB
D06414 Dasatinib (USAN) <JP/US>
KIT (CD117)
D06414 Dasatinib (USAN) <JP/US>
EPH family
EPHA2
D06414 Dasatinib (USAN) <JP/US>
Non-receptor tyrosine kinases
SRC family
SRC
D06414 Dasatinib (USAN) <JP/US>
FYN
D06414 Dasatinib (USAN) <JP/US>
LCK
D06414 Dasatinib (USAN) <JP/US>
YES1
D06414 Dasatinib (USAN) <JP/US>
ABL family
BCR-ABL [HSA_VAR:25v1]
D06414 Dasatinib (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06414
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06414
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06414
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06414
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06414
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D06414
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00714 Dasatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00714 Dasatinib
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00714 Dasatinib
DG02924 UGT substrate
DG00714 Dasatinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 34
1 C8y C 13.3022 -5.7416
2 N5x N 13.3022 -7.1418
3 C8y C 14.5147 -7.8419
4 N5x N 15.7274 -7.1418
5 C8y C 15.7274 -5.7416
6 C8x C 14.5147 -5.0414
7 N1b N 12.0896 -5.0414
8 C8y C 10.8769 -5.7441
9 S2x S 9.7404 -4.9261
10 C8y C 8.6113 -5.7541
11 C8x C 9.0499 -7.0839
12 N5x N 10.4500 -7.0777
13 C1a C 14.5147 -9.2418
14 N1y N 16.9587 -5.0304
15 C1x C 18.1641 -5.7263
16 C1x C 19.3766 -5.0260
17 N1y N 19.3766 -3.6258
18 C1x C 18.1712 -2.9300
19 C1x C 16.9586 -3.6302
20 C1b C 20.5947 -2.9223
21 C1b C 21.8068 -3.6219
22 O1a O 22.9858 -2.9409
23 C5a C 7.4654 -4.9082
24 N1b N 6.1887 -5.4834
25 C8y C 5.0522 -4.6655
26 O5a O 7.4740 -3.5160
27 C8y C 5.0522 -3.2653
28 C8x C 3.8396 -2.5652
29 C8x C 2.6270 -3.2653
30 C8x C 2.6270 -4.6655
31 C8y C 3.8396 -5.3656
32 X Cl 6.2453 -2.5768
33 C1a C 3.8394 -6.7900
34 O0 O 20.3032 -8.7519
BOND 36
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 2
12 11 12 1
13 8 12 2
14 3 13 1
15 5 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 18 19 1
21 14 19 1
22 17 20 1
23 20 21 1
24 21 22 1
25 10 23 1
26 23 24 1
27 24 25 1
28 23 26 2
29 25 27 1
30 27 28 2
31 28 29 1
32 29 30 2
33 30 31 1
34 25 31 2
35 27 32 1
36 31 33 1
|
|---|
